Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma

Summary

This study is a single-armed, open-label, single-center phase II trial of signal transduction inhibitor number 571 (STI-571) systemic therapy in selective patients with metastatic melanoma, and aims to study the efficacy and safety. The primary endpoint is progression-free survival (PFS) and the second endpoints are overall response rate (ORR), overall survival (OS), 1-year OS and safety.

Timeline

Start

2008-12

Primary completion

2011-01

Completion

2011-01

Drugs

Indications